MYCN and neuroblastoma: In the local cohort, 60 samples (60/90; 67%) classified into neuroblastoma subclasses: 27 samples (27/90; 30%) into TMM negative, 26 samples (26/90; 29%) into MYCN type, and seven samples (7/90; 8%) into “ALT/TERT TMM positive” subclass (Fig. 1C).